Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Platelet Reactivity
- Sponsor
- Pierre Fontana
- Enrollment
- 110
- Locations
- 1
- Primary Endpoint
- proteome profile of platelet hyperreactivity
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.
Detailed Description
The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype. Main objective: * to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients Secondary objectives: * to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin * to determine genetic polymorphisms associated with platelet hyperreactivity
Investigators
Pierre Fontana
PI
University Hospital, Geneva
Eligibility Criteria
Inclusion Criteria
- •Documented symptomatic ischemic atherothrombotic disease treated by aspirin.
Exclusion Criteria
- •Known platelet disorder
- •Chronic treatment by antiplatelet drugs other than aspirin
- •Chronic anticoagulant treatment
- •Chronic non steroidal anti-inflammatory drug treatment
- •Active cancer
- •Treatment with serotonin reuptake inhibitors
Outcomes
Primary Outcomes
proteome profile of platelet hyperreactivity
Time Frame: cross sectional
to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients
Secondary Outcomes
- platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin(cross sectional)